Group 1: Market Performance - The Medical-Biomed/Biotech industry group saw a significant surge in 2025, ending the year with a nearly 34% gain [4] - Eli Lilly (LLY) stock is highlighted as a key pick, having achieved a roughly 37% gain in 2025, outperforming the S&P 500 [5] Group 2: Company Developments - Eli Lilly is noted for being the first in its group to reach a $1 trillion valuation [5] - The company is planning to acquire Ventyx Biosciences for $1.2 billion, which could benefit other companies like Neumora and Neurocrine [11] Group 3: Investment Strategies - Swing trading strategies for Eli Lilly stock include selling into strength, selling into weakness, and cutting losses quickly [8][9]